WO2006114312A2 - Vaccine - Google Patents
Vaccine Download PDFInfo
- Publication number
- WO2006114312A2 WO2006114312A2 PCT/EP2006/003918 EP2006003918W WO2006114312A2 WO 2006114312 A2 WO2006114312 A2 WO 2006114312A2 EP 2006003918 W EP2006003918 W EP 2006003918W WO 2006114312 A2 WO2006114312 A2 WO 2006114312A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hpv
- vaccine
- protein
- immunogenic fragment
- fragment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
Definitions
- the present invention relates to human papillomavirus (HPV) vaccines.
- Papillomaviruses are small DNA tumour viruses, which are highly species specific. So far, over 100 individual human papillomavirus (HPV) genotypes have been described. HPVs are generally specific either for the skin (e.g. HPV-I and -2) or mucosal surfaces (e.g. HPV-6 and -11) and usually cause benign tumours (warts) that persist for several months or years. Such benign tumours may be distressing for the individuals concerned but tend not to be life threatening, with a few exceptions.
- HPVs human papillomavirus
- HPVs are also associated with cancers, known as oncogenic HPV types.
- the strongest positive association between an HPV and human cancer is that which exists between HPV- 16 and HPV-18 and cervical carcinoma. Cervical cancer is the most common malignancy in developing countries, with about 500,000 new cases occurring in the world each year.
- HPV types which can cause cancer are types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
- Types 16 and 18 are those which have the highest association with cervical cancer.
- Types 31 and 45 are the types with the next highest association with a cancer risk (Munoz N, Bosch FX, de Sanjose S et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. N EnglJMed 2003; 348: 518-27.)
- VLPs HPV virus like particles
- WO2004/056389 discloses that an HPV 16, 18 VLP vaccine can provide cross protection against infection by HPV types other than 16 and 18. Statistically significant protection was observed against certain groups of HPV types . There is still a need for a vaccine that protects against multiple HPV types.
- the present invention relates to a vaccination schedule for protection against HPV infection and/or disease, the schedule comprising delivery of a first HPV vaccine comprising an Ll protein or immunogenic fragment thereof from at least HPV 16 and HPV 18, and a second HPV vaccine which does not comprise the HPV 16 and HPV 18 Ll components from the first vaccine, and which second vaccine comprises an Ll protein or immunogenic fragment thereof from at least one other oncogenic HPV type, wherein the first and second vaccines may be delivered in either order and delivery is separated by a suitable interval.
- the present invention further relates to a vaccination schedule for protection against HPV infection or disease, the schedule comprising delivery of a first HPV vaccine comprising an Ll protein or immunogenic fragment thereof from at least HPV 16 and HPV 18, and after a suitable interval a second HPV vaccine which does not comprise the HPV 16 and HPV 18 Ll components from the first vaccine, and which second vaccine comprises an Ll protein or immunogenic fragment thereof from at least one other oncogenic HPV type.
- the invention further relates to a method for prevention of HPV infection and/or disease, the method comprising delivery of a first HPV vaccine comprising an Ll protein or immunogenic fragment thereof from at least HPV 16 and HPV 18, and a second HPV vaccine which does not comprise the HPV 16 and HPV 18 Ll components from the first vaccine, and which second vaccine comprises an Ll protein or immunogenic fragment thereof from at least one other oncogenic HPV type, wherein the first and second vaccines may be delivered in either order and delivery is separated by a suitable time interval.
- the invention also relates to a method for prevention of HPV infection and/or disease, the method comprising delivery of a first HPV vaccine comprising an Ll protein or immunogenic fragment thereof from at least HPV 16 and HPV 18, and after a suitable interval a second HPV vaccine which does not comprise the HPV 16 and HPV 18 Ll components from the first vaccine, and which second vaccine comprises an Ll protein or immunogenic fragment thereof from at least one other oncogenic HPV types.
- the invention also relates to vaccine compositions of the invention per se.
- the invention also relates to kits comprising the first and second vaccine compositions of the invention.
- the invention relates to use of an HPV Ll protein or immunogenic fragment thereof from one first HPV type in the preparation of a medicament for boosting the immune response generated by an HPV Ll protein or immunogenic fragment thereof from a second, different HPV type.
- the Ll protein or fragment thereof from the second HPV type is in the form of a virus like particle and is used to boost the response generated by the Ll protein or fragment thereof from the first HPV type also in the form of a virus like particle.
- the invention also relates to the use of HPV Ll, preferably in the form of VLPs, from HPV strains which are not HPV 16, in boosting the response to HPV 16.
- the invention also relates to the use of Ll, preferably in the form of VLPs, from HPV strains which are not HPV 18, in boosting the response to HPV 18.
- the strains for boosting the immune response are those for which some level of cross protection is observed in Example 1, such as HPV 31, HPV 45 and HPV
- FIGS 1 and 5 illustrate the antibodies generated to HPV 16 with different prime and boost regimes.
- Figure 2 and 6 illustrate the antibodies generated to HPV 18 with different prime and boost regimes.
- Figure 3 and 7 illustrate the antibodies generated to HPV 31 with different prime and boost regimes.
- Figure 4 and 8 illustrate the antibodies generated to HPV 45 with different prime and boost regimes.
- Fig 9 illustrates a summary of the antibody responses in Figs 1-8.
- Fig 10 and 14 illustrates the % HPV 16 Ll specific T cells in the CD4+ population with different prime and boost regimes.
- Fig 11 and 15 illustrates the % HPV 18 Ll specific T cells in the CD4+ population with different prime and boost regimes.
- Fig 12 and 16 illustrates the % HPV31 Ll specific T cells in the CD4+ population with different prime and boost regimes.
- Fig 13 and 17 illustrates the % HPV45 Ll specific T cells in the CD4+ population with different prime and boost regimes.
- Fig 18 illustrates a summary of the CMI data in Figures 10-13.
- Cross protection may be considered as the protection afforded by a vaccine containing one HPV type against infection (incident or persistent) and/or disease caused by a different HPV type.
- Cross protection may be assessed by considering the vaccine efficacy (V. E.), wherein the V.E. is the % improvement in protection against infection or disease by the vaccine compared to a placebo group for a given type.
- Infection may be incident or persistent infection.
- Disease may be abnormal cytology, ASCUS, CINl, CIN2, CIN3 or cervical cancer related to HPV infection.
- Infection may be assessed by PCR, for example.
- Disease may be assessed by histological examination or analysis of biomarkers such as pl ⁇ .
- Some level of cross protection is considered to be present when the cross protection is statistically significantly higher than that given by a placebo.
- the level of cross protection is greater than 0% and up to 20%, up to 40%, up to 60%, up to 70%, up to 80%, or greater than 80%, as measured by the vaccine efficacy of an HPV vaccine against infection or disease caused by an HPV type not present in the vaccine, when compared to a placebo.
- types for which cross protection is observed might be used as a prime or boost for one another, after a suitable interval, as well as providing homologous protection, and may allow the number of vaccinations for any given HPV type to be reduced.
- the present invention relates to a vaccination schedule for protection against HPV infection or disease, the schedule comprising delivery of a first HPV vaccine comprising an Ll protein or immunogenic fragment thereof from at least HPV 16 and HPV 18, and a second HPV vaccine which does not comprise the HPV 16 and HPV 18 Ll components from the first vaccine, and which second vaccine comprises an Ll protein or immunogenic fragment thereof from at least one other oncogenic HPV type, wherein the first and second vaccines may be delivered in either order and delivery is separated by a suitable interval.
- a suitable interval may be 7 days, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4, months, 5 months, 6 months, 1 year.
- Vaccination schedules might then be 0, 1 months, or 0, 2 months, or 0, 4 months or 0, 6 months, for example.
- a suitable interval is one in which the boosting effect of the vaccine delivered second can be observed, for example by measurement of antibody titres or cell mediated immunity.
- a suitable interval is one in which the primary immune response has been provoked by delivery of a vaccine, as measured by serum antibody titres for example, before delivery of a second vaccine.
- a suitable interval is shortly after the peak of the primary response, typically the antibody response.
- this interval is from 2 - 26 weeks after the initial vaccination, suitably 2 - 22 weeks, 2-18 weeks, 2-14 weeks, 2-12 weeks, 2 - 10 weeks, 2- 8 weeks, 2-6 weeks, and in one aspect 1 month after the initial vaccination.
- Oncogenic HPV types include HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
- the first vaccine suitably comprises an Ll protein or immunogenic fragment thereof from HPV 16 and HPV 18 and the second vaccine suitably comprises an Ll protein or immunogenic fragment thereof from HPV 31 , or HPV 45 or HPV 52.
- a first vaccine comprises Ll protein or immunogenic fragment thereof from HPV 16 and HPV 18.
- the first vaccine includes Ll protein or immunogenic fragment thereof from additional HPV types, such as one or more of HPV types 31,33,35,39,45,51,52,56,58,59,66,68.
- the HPV type is HPV 33.
- the second vaccine excludes at least the HPV 16 and 18 antigens from the first vaccine and comprises an Ll protein or immunogenic fragment thereof from an HPV type shown to have a cross protective interaction with HPV 16 and/or HPV 18 herein, suitably HPV 31 and/or 45 and/or 52.
- the second vaccine may include additional types such as one or more of HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.
- the second vaccine comprises Ll protein or immunogenic fragment thereof from HPV 31 , and/or HPV 45.
- the second vaccine includes Ll protein or immunogenic fragment thereof from type 52.
- the second vaccine includes Ll protein or immunogenic fragment thereof from type 58.
- the invention thus relates to a vaccine composition
- a vaccine composition comprising an Ll protein or immunogenic fragment thereof from HPV 31 but excluding an Ll protein or immunogenic fragment thereof from at least HPV 16 and HPV 18.
- the invention also relates to a vaccine composition
- a vaccine composition comprising an Ll protein or immunogenic fragment thereof from HPV 45 but excluding an Ll protein or immunogenic fragment thereof from at least HPV 16 and HPV 18.
- the invention also relates to a vaccine composition
- a vaccine composition comprising an Ll protein or immunogenic fragment thereof from HPV 52 but excluding an Ll protein or immunogenic fragment thereof from at least HPV 16 and HPV 18.
- the second vaccine excludes all the HPV Ll containing antigens from the first vaccine.
- the first and second vaccines share no identical Ll proteins or identical complete protein fragments.
- use of identical antigens, the antigen being either whole Ll or a fragment thereof, in both the first and second vaccine is not preferred in this aspect.
- first and second vaccines do not share an HPV Ll protein or immunogenic fragment thereof from the same HPV type.
- the components of the first vaccine contain HPV species which are phylogenetically not closely related, such as HPV 16 and HPV 18.
- the components of the second vaccine contain HPV species which are phylogenetically not closely related, such as HPV 31 and HPV 45.
- HPV 16 and/or HPV 18 components in the first vaccine component protect against HPV infection and/or disease caused by at least one HPV type in the second vaccine.
- first and second vaccines of the invention comprise HPV Ll VLPs from the following HPV types: first vaccine a combination of HPV 16, HPV 18 and HPV 33.
- the first vaccine may contain additionally HPV 58.
- second vaccine a combination of HPV 31 , HPV 45 and optionally HPV 52 and /or HPV 58.
- the vaccine delivered second boosts the immune response against at least one component in the vaccine delivered first.
- Boosting can suitably be measured by, for example, antibody titres, using methods standard in the art such as ELISA.
- an HPV Ll protein or immunogenic fragment thereof is used for boosting cross reactive antibodies previously raised to a different HPV type.
- the invention relates to use of Ll protein or immunogenic fragment thereof from one HPV type in boosting the immune response against a second, different HPV type.
- the invention relates to use of Ll protein or immunogenic fragment thereof from one HPV type in boosting the immune response against a homologous HPV type.
- the invention relates to use of Ll protein or immunogenic fragment thereof from one HPV type in boosting the immune response against a second, different HPV type, wherein the second type is phylogenetically related to the first type.
- Phylogenetic relationships between HPV types are well known in the art (see e.g. de Villers et al. Virology. 2004 Jun 20;324(l): 17-27).
- papillomaviruses can be seen to fall into distinct species which are phylogenetically related. For example, in species 16 are found types 16, 31, 33. In species 7 are found types 18 and 45.
- the invention relates to use of HPV 31 Ll protein or immunogenic fragment thereof in the preparation of a medicament for boosting an immune response to (generated by) an HPV 16 vaccine comprising an Ll protein or fragment thereof.
- the invention relates to use of HPV 52 Ll protein or immunogenic fragment thereof in the preparation of a medicament for boosting an immune response to an HPV 16 vaccine comprising an Ll protein or fragment thereof.
- the invention relates to use of HPV 45 Ll protein or immunogenic fragment thereof in the preparation of a medicament for boosting an immune response to an HPV 18 vaccine comprising an Ll protein or fragment thereof.
- the invention relates to use of HPV 18 Ll protein or immunogenic fragment thereof in the preparation of a medicament for boosting an immune response to an HPV 45 vaccine comprising an Ll protein or fragment thereof.
- the invention relates to use of HPV 16 Ll protein or immunogenic fragment thereof in the preparation of a medicament for boosting an immune response to an HPV 31 vaccine comprising an Ll protein or fragment thereof.
- the invention relates to use of HPV 16 Ll protein or immunogenic fragment thereof in the preparation of a medicament for boosting an immune response to an HPV 52 vaccine comprising an Ll protein or fragment thereof.
- the present relates in one aspect to a vaccination schedule for protection against HPV infection or disease, the schedule comprising delivery of a first HPV vaccine comprising an Ll protein or immunogenic fragment thereof from at least HPV 16 and HPV 18, and after a suitable interval a second HPV vaccine which does not comprise the HPV 16 and HPV 18 Ll components from the first vaccine, and which second vaccine comprises an Ll protein or immunogenic fragment thereof from at least one other oncogenic HPV type.
- the components of the first and second vaccines as defined above can be delivered in reverse order.
- the first HPV to be delivered might comprise HPV 31 and HPV 45 antigens
- the second vaccine to be delivered comprises HPV 16 and HPV 18 antigens.
- the vaccines of the invention can additionally comprise, within the constraints of the invention, antigens from other HPV types, such as other antigenic oncogenic types (e.g. HPV 31,33,35,39,45,51,52,56,58,59,66,68.) , skin types (e.g. types 5, 8) and genital warts types (6, 11).
- HPV 31,33,35,39,45,51,52,56,58,59,66,68. e.g. HPV 31,33,35,39,45,51,52,56,58,59,66,68.
- skin types e.g. types 5, 8
- genital warts types 6, 11).
- each vaccine is capable of protection against persistent infection for HPV types present in the vaccine.
- each vaccine is capable of protection against incident infection for HPV types present in the vaccine.
- Example 1 Incident and persistent cervical infection are defined in Example 1.
- each vaccine is capable of protection against cyto logical abnormalities related to HPV infection (e.g. ASCUS, CIN 1, CIN2, CM3, cervical cancer), suitably cuased by types not present in the vaccine, such as HPV 31, 45 or 52.
- HPV infection e.g. ASCUS, CIN 1, CIN2, CM3, cervical cancer
- Ll proteins or protein fragments from additional HPV types can be included in the vaccine of the invention, such as skin types (in particular HPV 5 and 8) and types associated with genital warts, such as HPV 6 and 11. Types 6 and 11 are not considered oncogenic types herein.
- the vaccine can comprise HPV Ll protein components, preferably as virus like particles, in different amounts.
- HPV 16 and HPV 18 VLPs may be provided at a higher dose than other oncogenic types, such as HPV 33 or 58.
- HPV 16 and HPV 18 Ll only VLPs are provided at 20 ⁇ g per dose for human use.
- Other HPV VLPs may be used at a lower dose, such as 15 or lO ⁇ g per dose for human use.
- the vaccine may include an HPV early antigen, for example an antigen selected from the list consisting of HPV El, E2, E3, E4, E5, E6, E7 or E8.
- the vaccine may lack an HPV early antigen, for example an antigen selected from the list consisting of HPV El, E2, E3, E4, E5, E6, E7 or E8.
- a vaccine component of the invention is trivalent (contains an HPV Ll or fragment thereof from 3 different oncogenic HPV types).
- the vaccine is tetravalent.
- the vaccine is pentavalent.
- the vaccine is hexavalent.
- the vaccine is heptavalent.
- the vaccine is octavalent. Higher order valancies are also contemplated herein.
- the vaccine is at least tetravalent, or at least pentavalent, or at least hexavalent, or at least heptavalent or at least octavalent with respect to the oncogenic HPV types.
- the combined vaccines of the invention comprise between them Ll protein or immunogenic fragments thereof from 4, 5, 6, 7, 8, 9 or 10 different HPV types.
- the combination of HPV components within the vaccine does not significantly impact the immunogenicity of any one HPV component.
- there is no biologically relevant interference between HPV antigens in the combination of the invention such that the combined vaccine of the invention is able to offer effective protection against infection by each HPV genotype represented in the vaccine.
- the immune response against a given HPV type in the combination is at least 50 % of the immune response of that same HPV type when measured individually, preferably 100% or substantially 100%.
- the combined vaccine of the invention preferably stimulates an immune response which is at least 50% of that provided by a combined HPV 16 / HPV 18 vaccine.
- the immune response generated by the vaccine of the invention is at a level in which the protective effect of each HPV type is still seen.
- the immune response may suitably be measured, for example, by antibody responses, in either preclinical or human experiments. Measurement of antibody responses is well known in the art, and disclosed in (for example) WO03/077942.
- suitable immunogenic fragments of HPV Ll include truncations, deletions, substitution, or insertion mutants of Ll .
- Such immunogenic fragments are suitably capable of raising an immune response (if necessary, when adjuvanted), said immune response being capable of recognising an Ll protein such as a virus like particle, from the HPV type from which the Ll protein was derived.
- a suitable immunogenic fragment of HPV 16 is capable of cross protection against at least one of HPV 31 and HPV 52, and in an aspect of the invention, capable of cross protection against both.
- a suitable immunogenic fragment of HPV 18 is capable of cross protection against HPV 45.
- Cross protection obtainable by immunogenic fragments of HPV 16 and/or HPV 18 can be assessed by trials in humans, for example as outlined in Example 1.
- vaccines according to the present invention can be tested using standard techniques, for example as in Example 1, or in standard preclinical models, to confirm that the vaccine is immunogenic.
- Suitable immunogenic Ll fragments include truncated Ll proteins.
- the truncation removes a nuclear localisation signal.
- the truncation is a C terminal truncation.
- the C terminal truncation removes fewer than 50 amino acids, such as fewer than 40 amino acids.
- the Ll is from HPV 16 then in another aspect the C terminal truncation removes 34 amino acids from HPV 16 Ll.
- the Ll is from HPV 18 then in a further aspect the C terminal truncation removes 35 amino acids from HPV 18 Ll.
- HPV 16 sequence is the following sequence: (SEQ ID NO: 1)
- the invention relates to virus like particles consisting only of HPV 16 Ll having the amino sequence above, and to compositions containing such VLPs.
- HPV 16 sequence may also be that disclosed in WO9405792 or US6649167, for example, suitably truncated. Suitable truncates are truncated at a position equivalent to that shown above, as assessed by sequence comparison.
- HPV 18 sequence is the following sequence: (SEQ ID NO: 2)
- the invention relates to virus like particles consisting only of HPV 18 Ll having the amino sequence above, and to compositions containing such VLPs.
- HPV 18 sequence is disclosed in WO9629413, which may be suitably truncated. Suitable truncates are truncated at a position equivalent to that shown above, as assessed by sequence comparison.
- HPV 16 and HPV 18 sequences are well known in the art and may be suitable for use in the present invention.
- C terminal truncations corresponding to those made for HPV 16 and HPV 18 may be used, based upon DNA or protein sequence alignments. Suitable truncations of, for example, HPV 31, HPV 45, HPV 52, HPV 58, HPV 33 may also be made, in one aspect removing equivalent C terminal portions of the Ll protein to those described above, as assessed by sequence alignment.
- the invention relates to virus like particles consisting only of HPV 31 Ll having the amino sequence encoded by the sequence above, and to compositions containing such VLPs.
- the invention relates to virus like particles consisting only of HPV 45 Ll having the amino sequence encoded by the sequence above, and to compositions containing such VLPs.
- the Ll protein or fragment of the invention may optionally be in the form of a fusion protein, such as the fusion of the Ll protein with L2 or an early protein.
- HPV Ll protein is suitably in the form of a capsomer or virus like particle (VLP).
- VLPs may be used in the present invention.
- HPV VLPs and methods for the production of VLPs are well known in the art.
- VLPs typically are constructed from the Ll and optionally L2 structural proteins of the virus, see for example WO9420137, US5985610, W09611272, US6599508B1, US6361778B1, EP 595935.
- Any suitable HPV VLP may be used in the present invention which provides cross protection, such as an Ll or Ll + L2 VLP.
- the VLP is an Ll -only VLP.
- VLP formation can be assessed by standard techniques such as, for example, electron microscopy and dynamic laser light scattering.
- the VLP may comprise full length Ll protein.
- the Ll protein used to form the VLP is a truncated Ll protein, as described above.
- VLPs may be made in any suitable cell substrate such as yeast cells or insect cells e.g. baculovirus cells, and techniques for preparation of VLPs are well known in the art, such as WO9913056, US 6416945B1 , US 6261765B1 and US6245568, and references therein, the entire contents of which are hereby incorporated by reference.
- VLPS are suitably made by disassembly and reassembly techniques, which can provide for more stable and/or homogeneous papillomavirus VLPs.
- disassembly and reassembly techniques which can provide for more stable and/or homogeneous papillomavirus VLPs.
- McCarthy et al, 1998 “Quantitative Disassembly and Reassembly of Human Papillomavirus Type 11 Virus like Particles in Vitro" J. Virology 72(1):33-41, describes the disassembly and reassembly of recombinant Ll HPV 11 VLPs purified from insect cells in order to obtain a homogeneous preparation of VLP's.
- WO9913056 and US6245568 also describe disassembly/reassembly processes for making HPV VLPs.
- HPV VLPS are made as described WO9913056 or US6245568
- HPV Ll the invention may be combined with an adjuvant or imunostimulant such as, but not limited to, detoxified lipid A from any source and non-toxic derivatives of lipid A, saponins and other reagents capable of stimulating a THl type response.
- an adjuvant or imunostimulant such as, but not limited to, detoxified lipid A from any source and non-toxic derivatives of lipid A, saponins and other reagents capable of stimulating a THl type response.
- enterobacterial lipopolysaccharide is a potent stimulator of the immune system, although its use in adjuvants has been curtailed by its toxic effects.
- LPS enterobacterial lipopolysaccharide
- MPL monophosphoryl lipid A
- a further detoxified version of MPL results from the removal of the acyl chain from the 3-position of the disaccharide backbone, and is called 3-O-Deacylated monophosphoryl lipid A (3D-MPL). It can be purified and prepared by the methods taught in GB 2122204B, which reference also discloses the preparation of diphosphoryl lipid A, and 3-O-deacylated variants thereof.
- a suitable form of 3D-MPL is in the form of an emulsion having a small particle size less than 0.2 ⁇ m in diameter, and its method of manufacture is disclosed in WO 94/21292.
- Aqueous formulations comprising monophosphoryl lipid A and a surfactant have been described in WO9843670A2.
- the bacterial lipopolysaccharide derived adjuvants to be formulated in the compositions of the present invention may be purified and processed from bacterial sources, or alternatively they may be synthetic.
- purified monophosphoryl lipid A is described in Ribi et al 1986 (supra)
- 3-O-Deacylated monophosphoryl or diphosphoryl lipid A derived from Salmonella sp. is described in GB 2220211 and US 4912094.
- Other purified and synthetic lipopolysaccharides have been described (Hilgers et al., 1986, Int. Arch. Allergy.
- the bacterial lipopolysaccharide adjuvant is 3D-MPL.
- the LPS derivatives that may be used in the present invention are those immunostimulants that are similar in structure to that of LPS or MPL or 3D-MPL.
- the LPS derivatives may be an acylated monosaccharide, which is a sub-portion to the above structure of MPL.
- Saponins are taught in: Lacaille-Dubois, M and Wagner H. (1996. A review of the biological and pharmacological activities of saponins. Phytomedicine vol 2 pp 363- 386). Saponins are steroid or triterpene glycosides widely distributed in the plant and marine animal kingdoms. Saponins are noted for forming colloidal solutions in water which foam on shaking, and for precipitating cholesterol. When saponins are near cell membranes they create pore-like structures in the membrane which cause the membrane to burst. Haemolysis of erythrocytes is an example of this phenomenon, which is a property of certain, but not all, saponins.
- Saponins are known as adjuvants in vaccines for systemic administration.
- the adjuvant and haemolytic activity of individual saponins has been extensively studied in the art (Lacaille-Dubois and Wagner, supra).
- Quil A derived from the bark of the South American tree Quillaja Saponaria Molina
- Serrev Ther Drug Carrier Sy st 1996, 12 (l-2):l-55
- EP 0 362 279 Bl are known as adjuvants in vaccines for systemic administration.
- IDS Immune Stimulating Complexes
- Quil A fractions of Quil A are haemolytic and have been used in the manufacture of vaccines (Morein, B., EP 0 109 942 Bl; WO 96/11711; WO 96/33739).
- the haemolytic saponins QS21 and QS 17 HPLC purified fractions of Quil A have been described as potent systemic adjuvants, and the method of their production is disclosed in US Patent No.5,057,540 and EP 0 362 279 Bl.
- Other saponins which have been used in systemic vaccination studies include those derived from other plant species such as Gypsophila and Saponaria (Bomford et al., Vaccine, 10(9):572-577, 1992).
- An enhanced system involves the combination of a non-toxic lipid A derivative and a saponin derivative particularly the combination of QS21 and 3D-MPL as disclosed in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as disclosed in WO 96/33739.
- a vaccine adjuvanted with detoxified lipid A or a non-toxic derivative of lipid A more suitably adjuvanted with a monophosphoryl lipid A or derivative thereof.
- the vaccine additionally comprises a saponin, for example QS21.
- the formulation additionally comprises an oil in water emulsion.
- the present invention also provides a method for producing a vaccine formulation comprising mixing an L2 peptide of the present invention together with a pharmaceutically acceptable excipient, such as 3D-MPL.
- a formulation comprises 3D-MPL, Triton X-IOO, Tween 80 and sodium deoxycholate, which may be combined with an L2 antigen preparation to provide a suitable vaccine.
- the vaccine comprises a vesicular adjuvant formulation comprising cholesterol, a saponin and an LPS derivative.
- the adjuvant formulation suitably comprises a unilamellar vesicle comprising cholesterol, having a lipid bilayer suitably comprising dioleoyl phosphatidyl choline, wherein the saponin and the LPS derivative are associated with, or embedded within, the lipid bilayer.
- these adjuvant formulations comprise QS21 as the saponin, and 3D-MPL as the LPS derivative, wherein the ratio of QS21 :cholesterol is from 1 :1 to 1 :100 weight/weight, and in one aspect, a ratio of 1 :5 weight/weight.
- Such adjuvant formulations are described in EP 0 822 831 B, the disclosure of which is incorporated herein by reference.
- the vaccines of the invention are used in combination with aluminium, and are suitably adsorbed or partially adsorbed onto aluminium adjuvants.
- the adjuvant is an aluminium salt, which may be in combination with 3D MPL, such as aluminium phosphate and 3D MPL. Aluminium hydroxide, optionally in combination with 3D MPL is also suitable.
- the vaccine comprises the combination of HPV VLPs with an aluminium salt or with an aluminium salt + 3D MPL.
- Aluminium hydroxide is suitable as the aluminium salt.
- the vaccine may also comprise aluminium or an aluminium compound as a stabiliser.
- the adjuvant may be a combination of an oil-in-water emulsion adjuvant and 3D MPL.
- the oil-in-water emulsion comprises a metabolisable oil, a sterol and an emulsifying agent.
- the vaccines of the invention may be provided by any of a variety of routes such as oral delivery (e.g. see WO9961052 A2) , topical, subcutaneous, mucosal (typically intravaginal), intraveneous, intramuscular, intranasal, sublingual, intradermal and via suppository.
- oral delivery e.g. see WO9961052 A2
- mucosal typically intravaginal
- intraveneous intramuscular
- intranasal sublingual
- intradermal via suppository.
- the vaccine may also be formulated or co-administered with other HPV antigens or non-HPV antigens.
- these non-HPV antigens can provide protection against other diseases, such as sexually transmitted diseases such as herpes simplex virus, EBV, chlamydia and HFV.
- the vaccine comprises gD or a truncate thereof from HSV. In this way the vaccine provides protection against both HPV and HSV.
- the dosage of the vaccine components will vary with the condition, sex, age and weight of the individual, the administration route and HPV of the vaccine.
- the quantity may also be varied with the number of VLP types.
- the delivery is of an amount of vaccine suitable to generate an immunologically protective response.
- each vaccine dose comprises 1-100 ⁇ g of each VLP, in one aspect 5-80 ⁇ g, in another aspect 5- 30 ⁇ g each VLP, in a further aspect 5-20 ⁇ g of each VLP, in a yet further aspect 5 ⁇ g, 6 ⁇ g, lO ⁇ g, 15 ⁇ g or 20 ⁇ g.
- the vaccine is used for the vaccination of adolescent girls aged 10-15, such as 10-13 years. However, older girls above 15 years old and adult women may also be vaccinated.
- the vaccine may also be administered to women following an abnormal pap smear or after surgery following removal of a lesion caused by HPV, or who are seronegative and DNA negative for HPV cancer types.
- the vaccine of the invention is used to vaccinate males.
- the vaccine is delivered in a 2 dose regime, for example in a 0, 1 month regime or 0, 6 month regime respectively.
- the vaccination regime may incorporate a booster injection after 5 to 10 years, such as 10 years.
- the invention relates to a three dose vaccine, in which (for example) a first vaccine and second vaccine are delivered, the first and second vaccine being different, followed by a third vaccine containing one or more or all of the HPV elements of the first or second vaccines.
- the first and second vaccines are completely different with respect to the HPV Ll components.
- a first vaccine may comprise or consist of HPV 16 and HPV 18 Ll protein.
- the second vaccine may consist of HPV 31 and HPV 45 Ll protein.
- a third vaccine may comprise Ll protein from all 4 HPV types, HPV 16, 18, 31 and 45.
- the invention in another aspect relates to a three dose vaccine, in which (for example) a first HPV vaccine and second HPV vaccine are delivered, the first and second vaccine being different, followed by a third vaccine, the third vaccine containing none of the HPV Ll components of the first or second vaccines.
- the vaccine is a liquid vaccine formulation, although the vaccine may be lyophilised and reconstituted prior to administration.
- the vaccines of the invention comprise certain HPV components as laid out above.
- the vaccine consists essentially of, or consists of, said components.
- 'vaccine' refers to a composition that comprises an immunogenic component capable of provoking an immune response in an individual, such as a human, optionally when suitably formulated or adjuvanted.
- a vaccine suitably elicts a protective immune response against incident infection, or persistent infection, or cytological abnormality such as ASCUS, CINl, CIN2 CIN3, or cervical cancer caused by one or more HPV types.
- the mixture comprised, per 0.5 ml dose, 20 ⁇ g of HPV- 16 Ll VLP, 20 ⁇ g of HPV- 18 Ll VLP and was adjuvanted with 500 ⁇ g of aluminum hydroxide and 50 ⁇ g of 3D MPL.
- the placebo group was injected with 500 ⁇ g of aluminum hydroxide alone.
- V. E. The vaccine efficacy (V. E.) against certain cancer HPV types was assessed, wherein the V. E. is the % improvement in protection against infection or disease by the vaccine compared to a placebo group.
- Cross protection was assessed by detecting the presence of nucleic acid specific for various oncogenic types in the vaccinees and control group. Detection was carried out using techniques as described in WO03014402, and references therein, particularly for non-specific amplification of HPV DNA and subsequent detection of DNA types using a LiPA system as described in WO 99/14377, and in Kleter et al, [Journal of Clinical Microbiology (1999), 37 (8): 2508-2517], the whole contents of which are herein specifically incorporated by reference.
- Any suitable method can, however, be used for the detection of HPV DNA in a sample, such as type specific PCR using primers specific for each HPV type of interest.
- Suitable primers are known to the skilled person, or can be easily constructed given that the sequences of the oncogenic HPV types are known.
- the primary objective of this study was to assess vaccine efficacy in the prevention of infection with HPV-16, HPV-18, or both (HPV-16/18), between months 6 and 18 in participants who were initially shown to be seronegative for HPV-16/18 by ELISA and negative for HPV- 16/18 DNA by PCR.
- Women eligible for the initial phase included healthy women aged 15- 25 years, who had had no more than six sexual partners, no history of an abnormal Pap test or ablative or excisional treatment of the cervix, and no ongoing treatment for external condylomata; and who were cytologically negative, seronegative for HPV- 16 and HPV- 18 antibodies by ELISA, and HPV-DNA-negative by PCR for 14 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) no more than 90 days before study entry. Women who completed the initial phase of the study earliest, and who did not have ablative or excisional therapy of the cervix, or hysterectomy after enrolment, were eligible to participate in the extension phase of the study (months 18-27).
- Each dose of the bivalent HPV- 16/18 virus-like particle vaccine contained 20 /*g of HPV-16 Ll virus-like particle and 20 Mg of HPV-18 Ll virus-like particle.
- Each type of virus-like particle was produced on Spodoptera frugiperda Sf-9 and Trichoplusia ni Hi-5 cell substrate with AS04 adjuvant containing 500 ⁇ g aluminum hydroxide and 50 Pg 3-deacylated monophosphoryl lipid A (MPL, Corixa, Montana, USA) provided in a monodose vial.
- the placebo contained 500 Pg of aluminum hydroxide per dose, and was identical in appearance to the HPV- 16/ 18 vaccine. Every study participant received a 0 5 mL dose of vaccine or placebo at 0 months, 1 month, and 6 months.
- Protocol guidelines recommended colposcopy after two reports of ASCUS, or one report of atypical glandular cells of undetermined significance, LSIL or HSIL, squamous cell carcinoma, adenocarcinoma in situ, or adenocarcinoma. These guidelines also recommended biopsy for any suspected lesions.
- the central histology laboratory made an initial diagnosis from the formalin-fixed tissue specimens for clinical management.
- a panel of three pathologists made a subsequent consensus diagnosis for HPV- 16 and HPV- 18 associated lesions with the CIN system. This consensus diagnosis also included review of the sections taken at the time of microdissection for PCR detection of lesional HPV DNA.
- HPV DNA isolated from the cytology specimen MagneticNaPure Total Nucleic Acid system, Roche Diagnostics, Almere, Netherlands
- cervical biopsy specimen proteinase K extraction
- SPFlO broad-spectrum primers that amplify a 65 bp region of the Ll gene.
- a line probe assay (LiPA Kit HPV DSfNO LiPA HPV genotyping assay, SPF-IO system version 1, Inno genetics, Gent, Belgium, manufactured by Labo Bio-medical Products, Rijswijk, Netherlands) detected 25 HPV genotypes (6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, and 74).
- HPV- 16 and HPV- 18 PCR Any specimen that was positive by DNA enzyme immunoassay was tested by type-specific HPV- 16 and HPV- 18 PCR.
- HPV- 16 type-specific PCR primers amplified a 92 bp segment of the E6/E7 gene and HPV- 18 type-specific PCR primers amplified a 126 bp segment of the Ll gene.
- MF Baay, WG Quint, J Koudstaal et al Comprehensive study of several general and type- specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin- embedded cervical carcinomas. J Clin Microbiol 34 (1996), pp. 745—747]
- HPV-DNA test results were concealed from investigators during the study and cytological and histological diagnoses were only revealed for clinical management purposes. Analyses included HPV- 16/18 DNA results for cervical specimens and combined cervical and self-obtained cervicovaginal specimens.
- Stratified, block randomisation according to validated algorithms was centralised with an internet randomisation system. Stratification was according to age (15-17, 18-21, and 22-25 years) and region (North America and Brazil). Each vaccine dose was attributed a randomly chosen number based on specific participant information entered into the computerised randomisation system by study personnel. Treatment allocation remains concealed from investigators and the women participating in a long-term follow-up study.
- the intention-to-treat and according-to-protocol cohorts are shown in the figure, in which the reasons for exclusion from analyses are listed in rank order; women who met more than one exclusion criterion were only counted once according to the highest ranking criterion.
- the cohort for safety analysis included all enrolled women who received at least one dose of vaccine or placebo and complied with specified, minimal protocol requirements (see figure below:)
- Immunogenicity was assessed in a subset of the according-to-protocol safety cohort, which included women with serology results at months 0, 7, and 18, who received all three doses of study vaccine or placebo according to schedule, complied with the blood sampling schedule, and did not become positive for HPV-16/18-DNA during the trial. Seropositivity rates between the vaccine and placebo groups were compared with Fisher's exact test (p ⁇ O001 judged significant). Geometric mean titres were compared with ANOVA and Kruskal-Wallis test.
- Tables B and C relate to the "ATP" (According To Protocol) group for those patients who complied with all the criteria of the trial.
- Table B is a midpoint analysis with data taken from all patients at the timepoint at which at least 50% of the cohort were 18 months after their first vaccination.
- Table C gives the final results, all data being from subjects at 18 months post first vaccination (month 0). hi the ATP group all patients received 3 doses of vaccine at 0, 1 and 6 months and were seronegative at 6 months.
- Table B demonstrates that HPV 16 and HPV 18 provide statistically significant cross protection against the group of high risk cancer types 31,33,35,39,45,51,52,56,58,59, 66 and 68.
- Table C demonstrates that, except for the HPV- 18 related types (which show a very strong trend), there is statistically significant cross-protection against the groups of: HPV 31, 35, 58; HPV 31, 33, 35, 52, 58; and the 12 high risk (non HPV- 16/18) types evaluated.
- Vaccine efficacy was assessed against infections and diseases related to the 12 high risk cancer types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68, HPV-16 phylogenetic-related types (the groups of; 31, 35, and 58; 31, 33, 35, 52 and 58) and HPV- 18 phylogenetic related types (45 and 59).
- Table B vaccine efficacy after three doses in preventing incident heterologous infections.
- N number of subjects in specific cohort n number of subjects with incident HPV infection
- Nv number of cases and non-cases in vaccine recipients
- np number of cases in placebo recipients
- Np number of cases and non-cases in placebo recipients
- HPV-16 related HPV-16 phylogenetically related types 35, 31, 58 without considering other HPV types
- HPV-16 related* HPV-16 phylogenetically related types 35, 31 , 58, 33, 52 without considering other HPV types
- HPV- 18 related HPV- 18 phylogenetically related types 45, 59 without considering other HPV types w HPV- 16 and/or HPV- 18 related: HP V- 16 and/or HPV- 18 phylogenetically related types 35, 31 , 58, 45, 59 without considering other HPV types
- HPV- 16 and/or HPV-18 related* HPV-16 and/or HPV-18 phylogenetically related types 35, 31 , 58, 33, 52, 45, 59 without considering other HPV types
- N number of subjects in specific cohort
- % Vaccine efficacy is 1 - (A/B) x 100, adjusted for relative size of vaccine and placebo group, wherein
- A % women in vaccine group with incident infection, persistent infection or cytological abnormality, as appropriate for the table
- mice 10 groups of C57B1/6 mice were used, containing 24 mice per group.
- mice were vaccinated according to the information below in a 2 dose schedule at day 0 and day 28, using intramuscular administration (1 group of mice were both primed and boosted with NaCl, not listed below).
- Vaccination was carried out using different HPV virus like particle combinations. 4 different VLPs were used: HPV 16 Ll only VLPs, HPV 18 Ll only VLPs, HPV 31 Ll only VLPs, and HPV 45 Ll only VLPs.
- VLPs were made and purified essentially according to the disclosure of WO2003077942A2, herein incorporated fully by reference.
- HPV 16 VLPs were purified using the sequential steps of: anion exchange chromatography (Di methyl amino ethyl - DMAE), anion exchange chromatography (tri methyl amino ethyl - TMAE), hydroxyapatite chromatography, filtration and another anion exchange step, this time using a Di ethyl amino ethyl (DEAE) step, followed by a final filtration.
- HPV 31 VLPs were made using the same sequence of steps.
- HPV 18 VLPs were purified using the sequential steps of: anion exchange chromatography (Di methyl amino ethyl - DMAE), anion exchange chromatography (tri methyl amino ethyl - TMAE), hydroxyapatite chromatography, filtration and an octyl sepharose column (hydrophobic interaction chromatography), followed by a final filtration.
- HPV 45 VLPs were made using the same sequence of steps.
- the adjuvant used was termed AS04D, at 1/10 of the human dose, which is 5 ⁇ g 3D MPL and 50 ⁇ g aluminium hydroxide in total for each vaccine.
- HPV virus like particles were combined with aluminium hydroxide and 3D MPL as disclosed in WO00/23105.
- the 3D-MPL and VLPs were then mixed, and additional aluminium hydroxide added to result in 50 ⁇ g per vaccine dose.
- Antibody titres were determined using classical ELISA techniques well known in the art at day 14 post the initial vaccination and second vaccination (post I and post II respectively). Intracellular staining (ICS, Roederer et al. 2004 Clin. Immunol. 110: 199) was carried out at 14 days post II to assess CMI responses.
- results are given in Figures 1 - 18 below.
- post I and post II data are measurements after vaccine dose I and II respectively.
- the bar given as "post I booster” reflects the group in which NaCl was given first, followed by either a bivalent or tetravalent vaccine dose at day 28.
- Figures 1-9 illustrate the antibody responses generated by different vaccination regimes.
- Figures 10 - 18 illustrate the CMI responses generated by different vaccination regimes.
- a heterologous booster comprised of HPV 31 and 45 Ll VLPs is effective in boosting homologous HPV 16 and 18 Ll VLP responses induced by HPV 16 and 18 Ll VLP priming.
- a heterologous booster comprised of HPV 31 and 45 Ll VLPs is effective in boosting heterologous HPV 31 and 45 Ll VLP responses induced by HPV 16 and 18 Ll VLP priming.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2007013472A MX2007013472A (en) | 2005-04-26 | 2006-04-24 | Vaccine. |
CA002606092A CA2606092A1 (en) | 2005-04-26 | 2006-04-24 | Vaccine |
US11/912,687 US20090181052A1 (en) | 2005-04-26 | 2006-04-24 | Vaccine |
EP06724609A EP1877086A2 (en) | 2005-04-26 | 2006-04-24 | Vaccine |
AU2006239422A AU2006239422A1 (en) | 2005-04-26 | 2006-04-24 | Vaccine |
EA200702079A EA013326B1 (en) | 2005-04-26 | 2006-04-24 | Vaccine |
BRPI0610032-5A BRPI0610032A2 (en) | 2005-04-26 | 2006-04-24 | use of a human papillomavirus l1 protein or immunogenic fragment thereof from a first type of hpv, vaccination program for protection against hiv infection and / or disease, method for preventing hpv infection and / or disease, vaccine composition and kit |
JP2008508156A JP2008539184A (en) | 2005-04-26 | 2006-04-24 | vaccine |
IL186586A IL186586A0 (en) | 2005-04-26 | 2007-10-11 | Vaccine |
NO20075194A NO20075194L (en) | 2005-04-26 | 2007-10-11 | vaccine |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67482905P | 2005-04-26 | 2005-04-26 | |
US60/674,829 | 2005-04-26 | ||
GB0509010.5 | 2005-05-03 | ||
GB0509010A GB0509010D0 (en) | 2005-05-03 | 2005-05-03 | Vaccine |
PCT/EP2005/006461 WO2005123125A1 (en) | 2004-06-16 | 2005-06-14 | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 |
EPPCT/EP2005/006461 | 2005-06-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006114312A2 true WO2006114312A2 (en) | 2006-11-02 |
WO2006114312A3 WO2006114312A3 (en) | 2007-04-05 |
Family
ID=36992675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/003918 WO2006114312A2 (en) | 2005-04-26 | 2006-04-24 | Vaccine |
Country Status (12)
Country | Link |
---|---|
US (1) | US20090181052A1 (en) |
EP (1) | EP1877086A2 (en) |
JP (1) | JP2008539184A (en) |
KR (1) | KR20080005585A (en) |
AR (1) | AR054259A1 (en) |
AU (1) | AU2006239422A1 (en) |
CA (1) | CA2606092A1 (en) |
EA (1) | EA013326B1 (en) |
MX (1) | MX2007013472A (en) |
NO (1) | NO20075194L (en) |
SG (1) | SG159525A1 (en) |
WO (1) | WO2006114312A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2364724A1 (en) | 2005-12-13 | 2011-09-14 | GlaxoSmithKline Biologicals S.A. | Vaccine compositions comprising a saponin adjuvant |
JP2011529475A (en) * | 2008-07-31 | 2011-12-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Anti-HPV vaccine |
EP2444103A1 (en) * | 2009-06-19 | 2012-04-25 | Eyegene Inc. | Vaccine for cervical cancer |
WO2012177970A1 (en) | 2011-06-24 | 2012-12-27 | Merck Sharp & Dohme Corp. | Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same |
WO2021163002A1 (en) | 2020-02-14 | 2021-08-19 | Merck Sharp & Dohme Corp. | Hpv vaccine |
WO2023014853A1 (en) | 2021-08-06 | 2023-02-09 | Merck Sharp & Dohme Llc | Hpv vaccine |
WO2023023152A1 (en) | 2021-08-19 | 2023-02-23 | Merck Sharp & Dohme Llc | Thermostable lipid nanoparticle and methods of use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001097840A1 (en) * | 2000-06-21 | 2001-12-27 | Medimmune, Inc. | Chimeric human papillomavirus (hpv) l1 molecules and uses therefor |
WO2003077942A2 (en) * | 2002-03-18 | 2003-09-25 | Glaxosmithkline Biologicals Sa | Virus-like particles of human papillomavirus |
WO2004056389A1 (en) * | 2002-12-20 | 2004-07-08 | Glaxosmithkline Biologicals Sa | Hpv-16 and -18 l1 vlp vaccine |
WO2005032586A1 (en) * | 2003-09-29 | 2005-04-14 | Merck & Co., Inc. | Optimized expression of hpv 45 l1 in yeast |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9921147D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB0105606D0 (en) * | 2001-03-07 | 2001-04-25 | Cantab Pharmaceuticals Res Ltd | Immunogens and vaccines and their preparation and use |
-
2006
- 2006-04-24 CA CA002606092A patent/CA2606092A1/en not_active Abandoned
- 2006-04-24 AR AR20060101619A patent/AR054259A1/en not_active Application Discontinuation
- 2006-04-24 EA EA200702079A patent/EA013326B1/en not_active IP Right Cessation
- 2006-04-24 EP EP06724609A patent/EP1877086A2/en not_active Ceased
- 2006-04-24 MX MX2007013472A patent/MX2007013472A/en unknown
- 2006-04-24 AU AU2006239422A patent/AU2006239422A1/en not_active Abandoned
- 2006-04-24 KR KR1020077027497A patent/KR20080005585A/en not_active Application Discontinuation
- 2006-04-24 WO PCT/EP2006/003918 patent/WO2006114312A2/en active Application Filing
- 2006-04-24 SG SG201000794-6A patent/SG159525A1/en unknown
- 2006-04-24 US US11/912,687 patent/US20090181052A1/en not_active Abandoned
- 2006-04-24 JP JP2008508156A patent/JP2008539184A/en active Pending
-
2007
- 2007-10-11 NO NO20075194A patent/NO20075194L/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001097840A1 (en) * | 2000-06-21 | 2001-12-27 | Medimmune, Inc. | Chimeric human papillomavirus (hpv) l1 molecules and uses therefor |
WO2003077942A2 (en) * | 2002-03-18 | 2003-09-25 | Glaxosmithkline Biologicals Sa | Virus-like particles of human papillomavirus |
WO2004056389A1 (en) * | 2002-12-20 | 2004-07-08 | Glaxosmithkline Biologicals Sa | Hpv-16 and -18 l1 vlp vaccine |
WO2005032586A1 (en) * | 2003-09-29 | 2005-04-14 | Merck & Co., Inc. | Optimized expression of hpv 45 l1 in yeast |
Non-Patent Citations (6)
Title |
---|
DA SILVA D M ET AL: "Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 21, no. 23, 4 July 2003 (2003-07-04), pages 3219-3227, XP004429731 ISSN: 0264-410X * |
DE VILLIERS E-M ET AL: "Classification of papillomaviruses" VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 324, no. 1, 20 June 2004 (2004-06-20), pages 17-27, XP004512668 ISSN: 0042-6822 cited in the application * |
KOWALCZYK D W ET AL: "Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 25-26, 14 May 2001 (2001-05-14), pages 3583-3590, XP004238957 ISSN: 0264-410X * |
QIAN JIAHUA ET AL: "Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice" INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 118, no. 12, 15 June 2006 (2006-06-15), pages 3022-3029, XP002396698 ISSN: 0020-7136 * |
VAN DER BURG S H ET AL: "Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 27, 14 June 2001 (2001-06-14), pages 3652-3660, XP004241783 ISSN: 0264-410X -& WO 02/070004 A2 (XENOVA RES LTD [GB]; LEIDEN UNIVERSITY MEDICAL CT [NL]; HICKLING JULIA) 12 September 2002 (2002-09-12) * |
VILLA L L ET AL: "Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial" LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 6, no. 5, 7 April 2005 (2005-04-07), pages 271-278, XP004870902 ISSN: 1470-2045 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10039823B2 (en) | 2005-12-13 | 2018-08-07 | Glaxosmithkline Biologicals, S.A. | Vaccine compositions comprising a saponin adjuvant |
US10143745B2 (en) | 2005-12-13 | 2018-12-04 | GlacoSmithKline Biologicals, S.A. | Vaccine compositions comprising a saponin adjuvant |
EP2364722A1 (en) | 2005-12-13 | 2011-09-14 | GlaxoSmithKline Biologicals S.A. | Vaccine compositions comprising a saponin adjuvant |
EP2364723A1 (en) | 2005-12-13 | 2011-09-14 | GlaxoSmithKline Biologicals S.A. | Vaccine compositions comprising a saponin adjuvant |
EP2364720A1 (en) | 2005-12-13 | 2011-09-14 | GlaxoSmithKline Biologicals S.A. | Vaccine compositions comprising a saponin adjuvant |
EP2364721A1 (en) | 2005-12-13 | 2011-09-14 | GlaxoSmithKline Biologicals S.A. | Vaccine compositions comprising a saponin adjuvant |
EP2364724A1 (en) | 2005-12-13 | 2011-09-14 | GlaxoSmithKline Biologicals S.A. | Vaccine compositions comprising a saponin adjuvant |
JP2011529475A (en) * | 2008-07-31 | 2011-12-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Anti-HPV vaccine |
EP2444103A1 (en) * | 2009-06-19 | 2012-04-25 | Eyegene Inc. | Vaccine for cervical cancer |
EP2444103A4 (en) * | 2009-06-19 | 2013-12-18 | Eyegene Inc | Vaccine for cervical cancer |
WO2012177970A1 (en) | 2011-06-24 | 2012-12-27 | Merck Sharp & Dohme Corp. | Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same |
WO2021163002A1 (en) | 2020-02-14 | 2021-08-19 | Merck Sharp & Dohme Corp. | Hpv vaccine |
WO2023014853A1 (en) | 2021-08-06 | 2023-02-09 | Merck Sharp & Dohme Llc | Hpv vaccine |
WO2023023152A1 (en) | 2021-08-19 | 2023-02-23 | Merck Sharp & Dohme Llc | Thermostable lipid nanoparticle and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2006114312A3 (en) | 2007-04-05 |
JP2008539184A (en) | 2008-11-13 |
US20090181052A1 (en) | 2009-07-16 |
SG159525A1 (en) | 2010-03-30 |
EP1877086A2 (en) | 2008-01-16 |
KR20080005585A (en) | 2008-01-14 |
EA013326B1 (en) | 2010-04-30 |
AU2006239422A1 (en) | 2006-11-02 |
MX2007013472A (en) | 2008-04-02 |
CA2606092A1 (en) | 2006-11-02 |
AR054259A1 (en) | 2007-06-13 |
EA200702079A1 (en) | 2008-04-28 |
NO20075194L (en) | 2008-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050287161A1 (en) | Vaccine | |
US20090181052A1 (en) | Vaccine | |
EP1758609B1 (en) | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 | |
JP2012102132A (en) | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 | |
US7858098B2 (en) | Vaccine | |
US7758866B2 (en) | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 | |
CN101217976A (en) | Vaccine | |
WO2006114273A2 (en) | Vaccine | |
CN101217975A (en) | Vaccine | |
BRPI0610032A2 (en) | use of a human papillomavirus l1 protein or immunogenic fragment thereof from a first type of hpv, vaccination program for protection against hiv infection and / or disease, method for preventing hpv infection and / or disease, vaccine composition and kit | |
BRPI0610396A2 (en) | multivalent hpv vaccine, methods to protect a patient against infection, to prevent or reduce the frequency of cytological abnormalities in a patient, to prevent the formation of histologically confirmed lesions and to manufacture the vaccine, and, uses of a composition, to a vaccine and a vaccine composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 186586 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 562526 Country of ref document: NZ Ref document number: 3957/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006239422 Country of ref document: AU Ref document number: 2008508156 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2606092 Country of ref document: CA Ref document number: 12007502367 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/013472 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 07114248 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2006239422 Country of ref document: AU Date of ref document: 20060424 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006239422 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006724609 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2007000728 Country of ref document: DZ |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200702502 Country of ref document: VN Ref document number: 1020077027497 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200702079 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680023032.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06724609 Country of ref document: EP Kind code of ref document: A2 |
|
WWP | Wipo information: published in national office |
Ref document number: 2006724609 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11912687 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0610032 Country of ref document: BR Kind code of ref document: A2 Effective date: 20071026 |